{{Rsnum
|rsid=1566652
|Gene=SLC6A2
|Chromosome=16
|position=55697663
|Orientation=plus
|GMAF=0.2815
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(G;G)
|geno2=(G;T)
|geno3=(T;T)
|Gene_s=SLC6A2
}}{{ population diversity
| geno1=(G;G)
| geno2=(G;T)
| geno3=(T;T)
| CEU | 45.1 | 45.1 | 9.7
| HCB | 45.3 | 42.3 | 12.4
| JPT | 48.7 | 40.7 | 10.6
| YRI | 83.7 | 16.3 | 0.0
| ASW | 70.2 | 28.1 | 1.8
| CHB | 45.3 | 42.3 | 12.4
| CHD | 50.5 | 43.1 | 6.4
| GIH | 50.5 | 42.6 | 6.9
| LWK | 94.5 | 5.5 | 0.0
| MEX | 37.9 | 46.6 | 15.5
| MKK | 74.4 | 24.4 | 1.3
| TSI | 32.4 | 50.0 | 17.6
| HapMapRevision=28
}}G allele associated with better response to treatment of [[ADHD]] with [[atomoxetine]]. {{PMID|19387424}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | Illumina Human 1M}}